TrialMedical oncology (Northwood, London, England)2014

Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.

Hasan Mutlu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.